A Single Dose of Any of Four Different Live Attenuated Tetravalent Dengue Vaccines Is Safe and Immunogenic in Flavivirus-naive Adults: A Randomized, Double-blind Clinical Trial

Abstract

TV003 induced a trivalent or greater antibody response in 90% of flavivirus-naive vaccinees and is a promising candidate for the prevention of dengue. Race was identified as a factor influencing the infectivity of the LATV viruses, reflecting observations of the effect of race on disease severity in natural dengue infection.

Advances in Dengue Vaccine: A Review Study

“…It was also found that trivalent or better response correlated with rash and with non-black race. Black race was significantly associated with reduced incidence of vaccine viremia [29]. This reflects the effect of race on disease severity in natural dengue infection.…”

“…They reported that the vaccination significantly reduced the incidence of virologically confirmed dengue and showed acceptable and safer reactogenicity profiles [28]. In another randomized, placebocontrolled study, Durbina et al [29] evaluated the safety and immunogenicity of four different tetravalent dengue vaccines was evaluated in 113 flavivirus-naïve adults. The serum neutralizing antibody levels to all four dengue vaccines were measured on days 0, 28, 48, and 180.…”

“…Furthermore, chimeric vaccine candidate were developed by the substitution of prM and E genes from each of the rDEN4∆30 vaccine candidates. Five of these formulations, designated as TV001-TV005 ( Figure 2) were evaluated in clinical studies [29,41].…”

Recent advances in human flavivirus vaccines

“…Earlier clinical trials demonstrated robust tetravalent antibody and T cell responses in 74% of the subjects after a single dose of TV003 [52,53]. The lowest serotype-specific response was obtained against DENV2 [53].…”

Live attenuated vaccine: the first clinically approved dengue vaccine?

“…Several approaches are in development: DENVax from Takeda (formerly Inviragen) and 30-DENV constructs (also referred to as live-attenuated trachoma vaccine [LATV]) from the National Institute of Allergy and Infectious Diseases have been tested in clinical tools and were found to be safe and immunogenic [10,11]. DENVax is based on the PDK53 DENV-2 backbone (a DENV-2 strain attenuated by serial passaging on PDK cells) and E and prM structural proteins were exchanged in the DENV-2 infectious cDNA clone to create the other serotypes.…”